| Literature DB >> 35736618 |
Urvish Patel1, Neel Patel1, Mahika Khurana2, Akshada Parulekar3, Amrapali Patel4, Juan Fernando Ortiz5, Rutul Patel6, Eseosa Urhoghide7, Anuja Mistry6, Arpita Bhriguvanshi8, Mohammed Abdulqader9, Neev Mehta10, Kogulavadanan Arumaithurai11, Shamik Shah12.
Abstract
Introduction: Tobacco use is one of the most significant risk factors for stroke. Besides traditional cigarettes and combustible products, the use of e-cigarettes and electronic nicotine delivery products has been widespread among young adults in the recent era. Furthermore, the trend of vaping has increased over the last decade. However, the relationship between e-cigarettes and stroke is largely unknown. The aim of this study was to evaluate the prevalence and identify the relationship between e-cigarette smoking and stroke.Entities:
Keywords: ENDS; NHANES; cerebrovascular disorders; e-cigarette; e-cigs; ischemic stroke; smoking; stroke risk factors; vaping
Year: 2022 PMID: 35736618 PMCID: PMC9227824 DOI: 10.3390/neurolint14020037
Source DB: PubMed Journal: Neurol Int ISSN: 2035-8385
Prevalence of stroke among various smoking habits among NHANES respondents 2015–2018 (n = 79,825).
| E-Cigarette Smokers | Dual E-Cigarette + Traditional Smokers | Traditional Smokers | Total | ||
|---|---|---|---|---|---|
| Stroke ( | 66 | 855 | 3273 | 4194 | <0.0001 |
| Age of onset of stroke in years | 48 (42–58) | 50 (40–58) | 59 (50–69) | <0.0001 |
Socio-demographics characteristics of various smoking habits among respondents with history of stroke (n = 4194).
| E-Cigarette Smokers with History of Stroke | Dual E-Cigarette + Traditional Smokers with History of Stroke | Traditional Smokers with History of Stroke | Total | ||
|---|---|---|---|---|---|
| Age in years at screening | 50 (45–63) | 55 (47–64) | 69 (62–80) | <0.0001 | |
| Sex (%) | <0.0001 | ||||
| Female | 36.36 | 51.93 | 33.91 | 37.63 | |
| Male | 63.64 | 48.07 | 66.09 | 62.37 | |
| Race (%) | <0.0001 | ||||
| Mexican-American | 21.21 | 11.58 | 6.02 | 7.39 | |
| Other Hispanic | 24.24 | 5.15 | 7.70 | 7.44 | |
| Non-Hispanic White | 37.88 | 47.13 | 42.77 | 43.59 | |
| Non-Hispanic Black | 0.00 | 24.09 | 31.29 | 29.33 | |
| Non-Hispanic Asian | 0.00 | 0.00 | 3.79 | 2.96 | |
| Other Race—Including Multi-Racial | 16.67 | 12.05 | 8.43 | 9.30 | |
| Annual Household Income (%) | <0.0001 | ||||
| $0–$25,000 | 57.58 | 59.15 | 50.67 | 52.44 | |
| $25,000–$65,000 | 16.67 | 32.18 | 32.49 | 32.16 | |
| $65,000–$100,000 | 25.76 | 4.27 | 7.99 | 7.57 | |
| >$100,000 | 0.00 | 4.41 | 8.85 | 7.83 | |
| Comorbidities (%) | |||||
| Coronary Heart Disease (%) | 25.76 | 15.32 | 27.62 | 25.08 | <0.0001 |
| Congestive Heart Failure (%) | 25.76 | 21.75 | 16.59 | 17.79 | <0.0001 |
| High Blood Pressure—2+ Times (%) | 60.98 | 98.02 | 80.91 | 84.11 | <0.0001 |
| Recent Systolic Blood Pressure in mmHg | 118 | 120 | 134 | <0.0001 | |
| Recent Diastolic Blood Pressure in mmHg | 70 | 80 | 80 | <0.0001 | |
| Taking Prescribed Medicine For HBP (%) | 100.00 | 81.66 | 89.33 | 87.89 | <0.0001 |
| High Cholesterol Level (%) | 25.76 | 60.58 | 58.11 | 58.11 | <0.0001 |
| Taking Prescribed Medicine High Cholesterol (%) | 100.00 | 82.52 | 84.39 | 81.83 | 0.2876 |
| LDL-Cholesterol, NIH Equation 2 (mg/dL) (Median) * | 112 | 101 | 110 | <0.0001 | |
| Diabetes (%) | 50.00 | 19.06 | 36.63 | 33.26 | <0.0001 |
| Last Hb A1C Level (Median) * | 5.7 | 7.2 | 7.9 | <0.0001 | |
| Feeling Down, Depressed, Or Hopeless (%) | <0.0001 | ||||
| Several Days | 12.12 | 17.56 | 18.24 | 17.99 | |
| More Than Half The Days | 0.00 | 13.59 | 8.91 | 9.73 | |
| Nearly Every Day | 21.21 | 19.87 | 7.46 | 10.29 | |
| Liver Disorders (%) | 21.21 | 6.43 | 9.84 | 9.32 | <0.0001 |
| Cancer Or Malignancy (%) | 25.76 | 17.19 | 24.35 | 22.91 | <0.0001 |
| Alcohol use disorder—Heavy drinking (%) † | 30.91 | 41.97 | 61.24 | 56.03 | <0.0001 |
| Marijuana or Hashish (%) | 100.00 | 92.15 | 66.20 | 78.61 | <0.0001 |
| Cocaine/Heroin/Methamphetamin (%) | 71.21 | 38.85 | 31.64 | 34.93 | <0.0001 |
| Inject Illegal Drug (%) | 21.21 | 1.77 | 4.63 | 4.63 | <0.0001 |
Percentage in brackets are column %, indicating a direct comparison between e-cigarette users vs. dual smokers vs. traditional smokers. * Due to positive skewed data and absence of 75th percentile (Q3) value, IQR for the median was not mentioned † Heavy drinking: for women, 8 or more drinks per week, and for men, 15 or more drinks per week.
Regression analysis showing relationship between various types of tobacco consumption and stroke.
| Variable | Multivariable Analysis * | c-Value (Area under ROC) |
|---|---|---|
| Possibility of having history of stroke = 1 | ||
| Non-smokers | Reference | |
| E-cigarette smokers vs. Traditional smokers | 1.15 (1.15–1.16); | 0.733 |
| Dual smokers vs. Traditional smokers | 1.14 (1.14–1.15); | |
| E-cigarette smoking in last 30-days vs. no-E-cigarette smoking in last 30-days | 1.60 (1.60–1.61); | 0.894 |
* Model for multivariable regression analysis was adjusted with sociodemographic variables like age, gender, race, annual household income, and comorbidities.
Potential vascular effects of e-cigarette components.
| Component Potentially Involved | Effect [ |
|---|---|
| Acrolein, PMs, nicotine | Increased blood pressure |
| Acrolein | Myocardial dysfunction and cardiomyopathy, impaired vascular repair, and vascular injury |
| Acrolein, PMs | Reduced cardiac contractility, Increased risk of thrombosis, increased risk of ventricular arrhythmias |
| PMs, nicotine | Coronary artery disease and myocardial infarction |
PMs: fine and ultrafine particulate matters.
Figure 1Acute and chronic effects of e-cigarettes smoking on cerebrovascular and cardiovascular systems.
Acute and chronic effects of e-cigarettes as a possible risk factor and trigger for stroke.
|
| |
| Kuntic et al. [ | E-cigarette product acrolein (reactive aldehydes) mediated NOX-2-driven oxidative stress and cerebrovascular inflammation |
| Caporale et al. [ | Transient impairment of cerebrovascular reactivity and endothelial function |
| Sifat et al. [ | Induces a state of glucose deprivation at the neurovascular unit, leading to enhanced ischemic brain injury and/or stroke risk |
|
| |
| Antoniewicz et al., | Increased HR; increased arterial stiffness is an independent risk factor for cardio and cerebrovascular events such as myocardial infarctions and stroke |
| Nocella et al. [ | Increase the soluble CD40L and P-selectin; enhance platelet aggregation |
| Boas et al. [ | Activation of splenocardiac axis (increase oxidative stress and increase sympathetic activity) |
| Carnevale et al. [ | Increase oxidative stress and endothelial dysfunction by increasing soluble NOX-mediated peptides and decreasing NO bioavailability and vitamin E |
|
| |
| Kuntic et al. [ | Endothelial dysfunction and narrowing of vessels |
| Kaisar et al. [ | Alter blood-brain barrier (BBB) permeability and vascular inflammation |
| Qasim et al. [ | In mice, alter physiological hemostasis and increase the risk of thrombogenic events; platelet activation |
|
| |
| Alzahrani et al. [ | Increased odds of having myocardial infarction (OR = 1.79, 95% CI = 1.20, 2.66, |
| Moheimani et al. [ | Increases in cardiac sympathetic activity and oxidative stress, both of which increase the risk of vascular disease |
| Frederik Franzen et al. [ | Increase peripheral and central blood pressure and pulse wave velocity |
| Vlachopoulos et al. [ | Increase aortic stiffness and increase blood pressure |